Heather Marriott, Renata Kabiljo, Ahmad Al Khleifat, Richard J Dobson, Ammar Al-Chalabi, Alfredo Iacoangeli
DNAscan2: a versatile, scalable, and user-friendly analysis pipeline for human next-generation sequencing data
Bioinformatics (Oxford, England)
better understand prevalence us valuebased payment arrangements vbas characteristics factors facilitate success act barriers implementation surveys administered convenience sample subject matter experts senior representatives payer organizations biopharmaceutical manufacturers data supplemented qualitative interviews subsample survey respondents descriptive statistics including percentages categorical values mean sd median interquartile range continuous variables assessed quantitative questions trained reviewers collated responses freetext survey questions qualitative interviews identify themes 25 respondents 1 manufacturer 4 payers reported explored negotiated vbas subsequently questionnaire results 11 biopharmaceutical manufacturers 9 payers experience vbas analyzed 70 vbas implemented 2014 2017 publicly disclosed furthermore although consideration vbas coverage payment tool increasing vba implementation relatively low manufacturers payers reporting approximately 33 60 early dialogues translate signed vba contracts respectively respondents reasoning vba negotiation process breakdowns generally differed sector reflected sectors respective priorities study reveals majority vbas publicly disclosed could underestimate true prevalence impact given effort required implement vba future arrangements would likely benefit framework evaluative tool help assess vba pursuit desirability guide negotiation implementation process